New study tracks how well ropeginterferon eases symptoms in polycythemia vera patients
NCT ID NCT06743035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 200 adults with polycythemia vera (a blood disorder) who do not have an enlarged spleen and are starting treatment with ropeginterferon alfa-2b. Researchers will track symptoms, blood cell counts, and side effects over 36 months in real-world clinics. The goal is to see how well the drug controls the disease and improves daily life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde
RECRUITINGHanover, Lower Saxony, 30161, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new drug reduce bloodletting for polycythemia vera?
- A simple Note-Taking change could transform blood cancer care
- Can a new drug help when standard treatment fails for polycythemia vera?
- New drug candidate targets Hard-to-Treat blood cancers